| Michael M Raso, MD | |
|
1115 N Bourland Ave, Peoria, IL 61606-1210 | |
| (309) 264-0730 | |
| Not Available |
| Full Name | Michael M Raso |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 22 Years |
| Location | 1115 N Bourland Ave, Peoria, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053518092 | NPI | - | NPPES |
| 036117194 | Other | IL | STATE MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 036117194 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Warner Hospital And Health Services | Clinton, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| City Of Clinton | 0042203127 | 13 |
| Skyline Wound Care Midwest Llc | 1658738281 | 4 |
| Epss Llc - East Series | 8729213459 | 7 |
News Archive
The human body has more than 600 muscles, which enable it to breathe, pump blood, move freely, lift things, and lead an active lifestyle.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.
Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first studies on the topic. The findings were published in the Journal of Medical Internet Research on January 29.
Exposure to cigarette smoke is known to increase the risk of asthma in childhood, but research findings on its later effects are scarce.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 1 days ago
| Entity Name | Sarah Bush Lincoln Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669564662 PECOS PAC ID: 5092614867 Enrollment ID: O20031231000478 |
News Archive
The human body has more than 600 muscles, which enable it to breathe, pump blood, move freely, lift things, and lead an active lifestyle.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.
Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first studies on the topic. The findings were published in the Journal of Medical Internet Research on January 29.
Exposure to cigarette smoke is known to increase the risk of asthma in childhood, but research findings on its later effects are scarce.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 1 days ago
| Entity Name | City Of Clinton |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275695470 PECOS PAC ID: 0042203127 Enrollment ID: O20040405001569 |
News Archive
The human body has more than 600 muscles, which enable it to breathe, pump blood, move freely, lift things, and lead an active lifestyle.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.
Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first studies on the topic. The findings were published in the Journal of Medical Internet Research on January 29.
Exposure to cigarette smoke is known to increase the risk of asthma in childhood, but research findings on its later effects are scarce.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 1 days ago
| Entity Name | Mcdonough County Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669420766 PECOS PAC ID: 0446140180 Enrollment ID: O20040611000228 |
News Archive
The human body has more than 600 muscles, which enable it to breathe, pump blood, move freely, lift things, and lead an active lifestyle.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.
Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first studies on the topic. The findings were published in the Journal of Medical Internet Research on January 29.
Exposure to cigarette smoke is known to increase the risk of asthma in childhood, but research findings on its later effects are scarce.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 1 days ago
| Entity Name | Blessingcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992038640 PECOS PAC ID: 2769420959 Enrollment ID: O20050419000684 |
News Archive
The human body has more than 600 muscles, which enable it to breathe, pump blood, move freely, lift things, and lead an active lifestyle.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.
Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first studies on the topic. The findings were published in the Journal of Medical Internet Research on January 29.
Exposure to cigarette smoke is known to increase the risk of asthma in childhood, but research findings on its later effects are scarce.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 1 days ago
| Entity Name | Epss Llc - East Series |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841533882 PECOS PAC ID: 8729213459 Enrollment ID: O20140213001518 |
News Archive
The human body has more than 600 muscles, which enable it to breathe, pump blood, move freely, lift things, and lead an active lifestyle.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.
Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first studies on the topic. The findings were published in the Journal of Medical Internet Research on January 29.
Exposure to cigarette smoke is known to increase the risk of asthma in childhood, but research findings on its later effects are scarce.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 1 days ago
| Entity Name | Skyline Wound Care Midwest Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295445179 PECOS PAC ID: 1658738281 Enrollment ID: O20230613000812 |
News Archive
The human body has more than 600 muscles, which enable it to breathe, pump blood, move freely, lift things, and lead an active lifestyle.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.
Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first studies on the topic. The findings were published in the Journal of Medical Internet Research on January 29.
Exposure to cigarette smoke is known to increase the risk of asthma in childhood, but research findings on its later effects are scarce.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael M Raso, MD 1115 N Bourland Ave, Peoria, IL 61606-1210 Ph: (309) 264-0730 | Michael M Raso, MD 1115 N Bourland Ave, Peoria, IL 61606-1210 Ph: (309) 264-0730 |
News Archive
The human body has more than 600 muscles, which enable it to breathe, pump blood, move freely, lift things, and lead an active lifestyle.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.
Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first studies on the topic. The findings were published in the Journal of Medical Internet Research on January 29.
Exposure to cigarette smoke is known to increase the risk of asthma in childhood, but research findings on its later effects are scarce.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
› Verified 1 days ago
Dr. Austin Lamb, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 530 N.e. Glen Oak Avenue, Osf St. Francis, Emergency Medicine Residency Program, Peoria, IL 61637 Phone: 309-655-7257 | |
Philip A Fifield, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 530 Ne Glen Oak Ave, Peoria, IL 61637 Phone: 309-655-2553 Fax: 309-655-2602 | |
Dr. Anthony J Buecker, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 221 Ne Glen Oak Ave, Peoria, IL 61636 Phone: 309-672-5500 | |
Dr. Mark Phillip Gaudio, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 530 Ne Glen Oak Ave, Peoria, IL 61637 Phone: 309-655-6710 | |
Ryan Newberger, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 530 Ne Glen Oak Ave, Peoria, IL 61637 Phone: 248-207-2018 | |
Craig D Koch, M.D Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 530 Ne Glen Oak Ave, Peoria, IL 61637 Phone: 309-655-7257 |